Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Agents. Found 201 abstracts

no pagination
Chu J, Gallo JM. Application of microdialysis to characterize drug disposition in tumors. Adv Drug Deliv Rev. 2000 Dec 15;45(2-3):243-53.
Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochemical pharmacology. 2000 Nov;60(9):1305-13.
Fowble B, Hanlon A, Freedman G, Nicolaou N, Hoffman J, Sigurdson E, Boraas M, Torosian M, Goldstein L. Internal mammary node irradiation neither decreases distant metastases nor improves survival in stage I and II breast cancer. Int J Radiat Oncol Biol Phys. 2000 Jul;47(4):883-94.
Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol. 2000 Jun;18(12):2459-67.
Langer CJ. The role of new agents in advanced non-small-cell lung carcinoma. Current oncology reports. 2000 Jan;2(1):76-89.
Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. Journal of the National Cancer Institute. 2000 Dec 06;92(23):1934-40.
Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res. 2000 Oct;60(19):5390-4.
Schwartz AL, Nail LM, Chen S, Meek P, Barsevick AM, King ME, Jones LS. Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest. 2000 Jan;18(1):11-9.
Young RC. The sounds of silence. Nature. 2000 Nov 09;408(6809):141.
Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. The oncologist. 1999 Jan;4(2):87-94.
Ozols RF. Oncology: current trends in the treatment of advanced ovarian cancer. Journal of Care Management. 1999 Aug;5(4):Disease Manage Digest: 6-7.
Dresler CM. Kidney metastases. Chest Surg Clin N Am. 1998 Feb;8(1):127-9.
Sokol DB, Hudes GR. Cisplatin-based chemotherapy for testicular cancer in a patient with spinal muscular atrophy: a case report. Am J Clin Oncol. 1998 Aug;21(4):420-1.
Tew KD, O'Brien M, Laing NM, Shen H. Coordinate changes in expression of protective genes in drug-resistant cells. Chem Biol Interact. 1998 Apr 24;111-112:199-211.
Fowble B. Postmastectomy radiation: then and now. Oncology (Huntingt). 1997 Feb;11(2):213-34, 239; discussion 239-40, 243.
Zhang X, Minale L, Zampella A, Smith CD. Microfilament depletion and circumvention of multiple drug resistance by sphinxolides. Cancer Res. 1997 Sep;57(17):3751-8.
Martin V. Ovarian cancer: an update on new directions in screening and treatment. Journal of Gynecologic Oncology Nursing. 1996 Jan;6(3):9-11.
Martin VR. On the horizon. Clinical review of docetaxel (TAXOTERE). Innovations in Breast Cancer Care. 1996 Oct;2(1):9-12.
Martin VR, Comis RL. Small cell carcinoma of the lung: an "updated" overview. Seminars in Oncology Nursing. 1996 Nov;12(4):295-303.
Hoier H, Carrell HL, Glusker JP, Spears CP. Structure of ethyl phenyl selenone. Acta Crystallogr C. 1993 Mar 15;49 ( Pt 3):520-3.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Agents

Antineoplastic Agents Human drug therapy Female US Gov't Support-PHS therapeutic use pharmacology metabolism physiology Non-US Gov't Support Cisplatin Ovarian Neoplasms dt [Drug Therapy] pathology Aged Cultured Tumor Cells Adult Middle Age Neoplasms Animal Male Breast Neoplasms radiotherapy genetics Phytogenic Antineoplastic Agents Lung Neoplasms Clinical Trials Paclitaxel drug effects Neoplasm Drug Resistance 80 and over Aged tu [Therapeutic use] Antitumor Drug Screening Assays Combined Modality Therapy Neoplasm Staging secondary Polymers Topotecan Multiple Drug Resistance ad [Administration and Dosage] prevention & control Protein-Serine-Threonine Kinases Local Neoplasm Recurrence Combination Drug Therapy Survival Analysis Prognosis methods Disease-Free Survival Continuing (Credit) Education chemistry surgery pharmacokinetics Enzyme Activation Infiltrating Duct Carcinoma Socioeconomic Factors Treatment Outcomes Fatigue Affect Age Factors epidemiology 3T3 Cells Porifera Camptothecin Cytotoxins Spinal Muscular Atrophy Smooth Muscle-Vascular Molecular Models Drug Approval DNA Repair Meta-Analysis Glutathione Cytochalasin B Carcinoma mortality ae [Adverse Effects] Non-Small-Cell Lung Carcinoma pr [Prognosis] Type II DNA Topoisomerases Cyclins Immunohistochemistry Salvage Therapy Magnetic Resonance Imaging Axilla Cancer Screening Carrier Proteins Follow-Up Studies Theoretical Models et [Etiology] DNA-Binding Proteins therapy Lymphatic Irradiation Prospective Studies Anthracycline Antibiotics Microfilaments biosynthesis Menopause X-Ray Diffraction Analysis of Variance Radiotherapy Dosage Adenosinetriphosphatase physiopathology Radiotherapy Cell Death Cell Survival Testicular Neoplasms Kidney Neoplasms Antineoplastic Antimetabolites Adolescent Methotrexate US Gov't Support-Non-PHS Drug Combinations Proteins Microdialysis United States Organoselenium Compounds Investigational Drugs Antineoplastic Combined Chemotherapy Protocols Transfection Molecular Structure Case Report cl [Classification] Cell Cycle Carboplatin DNA Fragmentation Adjuvant Chemotherapy Actins Vinblastine Hela Cells Quality of Life enzymology Drug Dose-Response Relationship th [Therapy] Pyrans Risk Factors Immunotherapy ultrastructure Ethacrynic Acid Phase I Clinical Trials Acrylates Doxorubicin Tumor Antigens Anion Transport Proteins pp [Physiopathology] Funding Source Signal Transduction Recurrence Type I DNA Topoisomerases Kidney Deoxycytidine Drug Resistance
Last updated on Friday, January 03, 2020